Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

55.70USD
12 Dec 2017
Change (% chg)

$0.76 (+1.38%)
Prev Close
$54.94
Open
$55.50
Day's High
$55.87
Day's Low
$55.16
Volume
2,356,631
Avg. Vol
1,521,203
52-wk High
$56.68
52-wk Low
$37.90

Latest Key Developments (Source: Significant Developments)

Abbott gets FDA clearance for its Alinity ci-series instruments
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Abbott Laboratories :Abbott announces FDA clearance for its Alinity ci-series next-generation diagnostic systems.Abbott laboratories - ‍secured U.S. FDA 510(k) clearance for its alinity ci-series instruments for clinical chemistry and immunoassay diagnostics​.  Full Article

Abbott says ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Abbott Laboratories :Abbott - ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​.  Full Article

Abbott CFO says Alere is expected to contribute around $475 mln to reported sales this year
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Abbott Laboratories :Abbott CFO says Alere, is expected to contribute around $475 million to reported sales, and forecast a neutral impact on adjusted earnings per share this year - Conf Call.Abbott CFO expects fourth quarter adjusted earnings per share of $0.72 to $0.74 - Conf Call.Abbott CFO expects Q4 comparable operational sales growth in the mid to high single-digits - Conf Call.Abbott CFO says "established pharmaceuticals, we forecast double-digit sales growth and in nutrition, we forecast low single-digit sales growth" in Q4 - Conf Call.Abbott CFO says "in diagnostics, we forecast sales to increase mid single-digits and in medical devices, we forecast sales to increase mid to high single-digits in Q4" - Conf Call.Abbott CEO on China nutrition business says "we've seen a stabilizing of China, it hasn't been as choppy as it was in the last 2 years".  Full Article

Abbott Q3 adjusted EPS $0.66 from continuing operations
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Abbott Laboratories ::Abbott reports third-quarter 2017 results.Sees FY 2017 gaap earnings per share $0.97 to $0.99 from continuing operations.Q3 adjusted earnings per share $0.66 from continuing operations.Q3 gaap earnings per share $0.32 from continuing operations.Q3 earnings per share view $0.65 -- Thomson Reuters I/B/E/S.Sees Q4 adjusted earnings per share $0.72 to $0.74 from continuing operations excluding items.Sees FY 2017 adjusted earnings per share $2.48 to $2.50 from continuing operations.Sees Q4 2017 gaap earnings per share $0.28 to $0.30 from continuing operations.Q3 sales $6.8 billion versus I/B/E/S view $6.72 billion.Abbott Laboratories - ‍narrowed its full-year 2017 eps guidance range​.Abbott Laboratories qtrly total pediatric sales $‍975​ million, up 0.8 percent on a reported basis.Abbott Laboratories qtrly total nutrition sales $1,768 million, up 0.8 percent on a reported basis‍​.Abbott Laboratories - qtrly total vascular sales $‍724​ million, up 17.1 percent on reported basis.Abbott Laboratories - qtrly total diagnostics sales $1,279 million, up 5.4 percent on a reported basis ‍​.Abbott Laboratories - ‍on Oct. 3, 2017, Abbott completed acquisition of Alere​.FY 2017 earnings per share view $2.50 -- Thomson Reuters I/B/E/S.Q4 earnings per share view $0.74 -- Thomson Reuters I/B/E/S.Abbott Laboratories - ‍expects to initiate launch of its alinity systems in U.S. In 2018​.  Full Article

Abbott Laboratories says ‍announced U.S. Launch of company's proclaim DRG neurostimulator system​
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Abbott Laboratories ::Abbott laboratories - ‍announced U.S. launch of company's proclaim DRG neurostimulator system​.  Full Article

Abbott acquisition of Alere set to close on October 3, 2017
Friday, 29 Sep 2017 

Sept 29 (Reuters) - Abbott Laboratories ::Abbott acquisition of Alere set to close on Tuesday, October 3, 2017.Abbott acquisition of Alere set to close on Tuesday, October 3, 2017.  Full Article

Abbott Laboratories says co & North West London Pathology signed a $252 mln managed equipment services contract
Tuesday, 15 Aug 2017 

Aug 15 (Reuters) - Abbott Laboratories :Abbott Laboratories- Co & North West London Pathology signed a $252 million managed equipment services contract.Abbott Laboratories - ‍Partnership is expected to manage 26 million tests per year and currently holds 6 percent of total pathology market in UK​.  Full Article

FDA approves Idhifa for treating relapsed/refractory Acute Myeloid Leukemia
Tuesday, 1 Aug 2017 

Aug 1 (Reuters) - U.S. FDA::U.S. FDA-Approved Idhifa (Enasidenib) for treatment of adult patients with relapsed/refractory Acute Myeloid Leukemia (AML) with specific genetic mutation.U.S. FDA - granted approval of Idhifa to Celgene corporation, granted approval of the realtime IDH2 assay to Abbott Laboratories.U.S. FDA-Idhifa approved for use with companion diagnostic realtime IDH2 assay which is used to detect specific mutations in IDH2 gene in AML patients.FDA-Prescribing information for Idhifa includes boxed warning, adverse reaction called Differentiation Syndrome can occur,can be fatal if not treated.  Full Article

Alere shareholders approve amended merger with Abbott
Saturday, 8 Jul 2017 

July 7 (Reuters) - Alere Inc :Alere shareholders approve amended merger with abbott.Alere says about 63 million of votes cast at special meeting voted in favor of amended merger, representing over 72.5 percent of alere shares as of may 31.  Full Article

Abbott Laboratories names John Stratton to its board
Friday, 30 Jun 2017 

June 29 (Reuters) - Abbott Laboratories ::Abbott Laboratories - ‍on June 29, 2017, John G. Stratton was named to Abbott Laboratories' board of directors, effective immediately​.Abbott Laboratories - ‍on June 28, 2017, Abbott's board of directors amended first sentence of article III, section 2 of Abbott's by-laws​.Abbott Laboratories says ‍amended by-laws to provide Abbott's board shall consist of twelve persons, effective as of June 29, 2017 - SEC filing.  Full Article

BRIEF-Abbott's mitraclip approved as first transcatheter mitral valve repair device in Japan

* Abbott's mitraclip approved as first transcatheter mitral valve repair device in Japan Source text for Eikon: Further company coverage: